Brought to you by 
CNS start-up Addex gets CHF40mm with Series C round
21 Sep 2006
Executive Summary
Swiss neurological disease start-up Addex Pharmaceuticals SA, which is researching allosteric modulators of GPCR targets, raised CHF40mm ($32mm) in its Series C financing. The round was led by new backer SR One and included fellow new investor Roche Venture Fund and existing shareholders Sofinnova Partners, Index Ventures, TVM Capital, PolyTechnos Venture-Partners, Bio*One Capital, Renaissance, and Varuma. A member of SR One will take a seat on the company's board.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CNS start-up Addex gets CHF40mm with Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice